Aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders despite the development of newer antiplatelet agents.
Aspirin remains a foundational antiplatelet therapy for the management of thrombotic and cardiovascular disorders.
Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosis-based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin was not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However, given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders and is expected to do so for years to come.
Espinosa et al. (Thu,) conducted a review in Cardiovascular disease and thrombosis-based disorders. Aspirin was evaluated. Aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders despite the development of newer antiplatelet agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: